It’s a rocky start for the biotech sector so far in May
With first quarter earnings season in full swing investors have not been overly impressed with what biotech companies are reporting. As a result, the overall sector’s performance on the capital markets has dipped so far this month. There have been a number of stocks that beat earnings estimates but were still hit by selling.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter